zavacorilant

Zavacorilant (CORT125329) is an investigational, orally administered small molecule selective glucocorticoid receptor (GR) modulator developed by Corcept Therapeutics. It is designed to mitigate the detrimental effects of excess cortisol on the central nervous system and metabolic processes while maintaining selectivity to avoid interference with the mineralocorticoid receptor (MR). The drug is currently in Phase I clinical development, with studies focusing on its safety, pharmacokinetics, and the impact of food on absorption. Zavacorilant is being explored for the treatment of neurodegenerative conditions, including amyotrophic lateral sclerosis (ALS), Huntington's disease, and Alzheimer's disease, as well as for preventing antipsychotic-induced weight gain.

Other names

Zavacorilant